MicroRNA‐130a inhibits HCV replication by restoring the innate immune response

Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis and hepatocellular carcinoma. Currently pegylated interferon (IFN) combined with ribavirin remains the best therapeutic approach, although patients infected with HCV genotype I may benefit from adding protease inhibitors as ‘triple therapy’. MicroRNAs (miRNAs) are endogenous small noncoding RNAs that regulate gene expression and have recently been shown to play an important role in human innate immune response and as an antiviral in chimpanzees. We studied the effect of miR‐130a on the HCV replication. We found that miR‐130a significantly inhibits HCV replication in both HCV replicon and J6‐/JFH1‐infected cells. Over expression of miR‐130a upregulated the expression of type I IFN (IFN‐α/IFN ‐β), ISG15, USP18 and MxA, which are involved in innate immune response and decreased expression of miR‐122, a well‐defined miRNA promoting HCV production. In conclusion, miR‐130a inhibits HCV replication/production by restoring host innate immune responses and/or downregulating pro‐HCV miR‐122. miR‐130a might be a potential drug target by modulating host innate immune responses to combat HCV infection.

[1]  H. Bonkovsky,et al.  Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[2]  Takaji Wakita,et al.  Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. , 2010, Virology.

[3]  Xinxia Peng,et al.  Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers , 2009, BMC Genomics.

[4]  E. Meurs,et al.  Hepatitis C Virus Controls Interferon Production through PKR Activation , 2010, PloS one.

[5]  Stefano Volinia,et al.  Interferon modulation of cellular microRNAs as an antiviral mechanism , 2007, Nature.

[6]  Ralf Bartenschlager,et al.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus , 2005, Nature.

[7]  K. Jeang,et al.  Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. , 2008, Cancer research.

[8]  T. Asselah,et al.  Gene expression and hepatitis C virus infection , 2008, Gut.

[9]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[10]  David Baltimore,et al.  MicroRNA-155 is induced during the macrophage inflammatory response , 2007, Proceedings of the National Academy of Sciences.

[11]  J. Justesen,et al.  Small ISGs coming forward. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  W. Cao,et al.  MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703. , 2011, Cancer letters.

[13]  L. Terracciano,et al.  Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. , 2003, Gastroenterology.

[14]  Yoshiki Murakami,et al.  Regulation of the hepatitis C virus genome replication by miR-199a. , 2009, Journal of hepatology.

[15]  T. Berg,et al.  Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. , 2010, Trends in molecular medicine.

[16]  Hong Cao,et al.  Cellular microRNA and P bodies modulate host-HIV-1 interactions. , 2009, Molecular cell.

[17]  C. Jopling.  Targeting microRNA-122 to Treat Hepatitis C Virus Infection , 2010, Viruses.

[18]  J. Stenvang,et al.  Inhibition of microRNA function by antimiR oligonucleotides , 2012, Silence.

[19]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[20]  Xiaojiao Zhang,et al.  microRNA‐1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down‐regulation in hepatocellular carcinoma , 2011, FEBS letters.

[21]  S. Zeuzem,et al.  Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[23]  S. Lemon,et al.  Regulation of Hepatitis C Virus Translation and Infectious Virus Production by the MicroRNA miR-122 , 2010, Journal of Virology.

[24]  G. Vaughan,et al.  Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naïve Infected Individuals , 2011, Journal of Clinical Microbiology.

[25]  P. Sarnow,et al.  Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA , 2005, Science.

[26]  V. Kim.  MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.

[27]  A. Saïb,et al.  A Cellular MicroRNA Mediates Antiviral Defense in Human Cells , 2005, Science.